• Biotechnology company, Ceapro (CZO) has successfully achieved the first milestone in developing an inhalable COVID-19 therapeutic
  • The milestone was optimising the size and structure of the best PGX-processed yeast beta glucans for modulating the immune system
  • With the first milestone fully achieved, the project’s second milestone is also nearing completion
  • The company hopes to begin planning and preparing a clinical trial protocol for the treatment in 2020’s fourth quarter
  • Ceapro (CZO) is up 14.49 per cent and is currently trading at C$0.79 per share

Biotechnology company, Ceapro (CZO) has successfully achieved the first milestone in developing an inhalable COVID-19 therapeutic.

The project is entitled “PGX-processed yeast beta glucans as an inhalable immunomodulating therapeutic for COVID-19 patients”. It is currently under the leadership of two experts in medicine and chemical engineering from McMaster University.

The project’s first milestone was to optimise the size and structure of the best PGX-processed yeast beta glucans for modulating the immune system. The research team was able to consistently generate PGX-processed yeast beta glucan particles that are small enough for effective inhalation.

The project’s second milestone is to examine tolerability and safety of inhaled PGX-YBG in naïve animal models. With the first milestone fully achieved, the second milestone is also nearing completion.

If the particles pass the tolerability, safety, and therapeutic animal tests, the material could become an immune modulator and anti-fibrotic treatment option. This would be of particular benefit to the most severe COVID-19 patients, who suffer from lung-related issues.

The third and fourth goals of the project could be completed as early as mid-October. If the pre-clinical results are favourable, Ceapro could begin preparing and planning a Phase ½ clinical trial protocol during 2020’s fourth quarter.

McMaster University’s Dr Todd Hoare commented on the success of the project thus far.

“We are excited that we have been able to fabricate particles that have the targeted properties for inhalation, enabling the effective delivery of the particles to patients’ lungs, pending the safety and efficacy animal trials now underway.

“As this project continues, our confidence in the potential of Ceapro’s materials to treat late-stage COVID-19 patients and make a real-time impact on preserving lives during the pandemic continues to build,” he said.

Ceapro (CZO) is up 14.49 per cent and is trading at C$0.79 per share at 1:46pm EDT.

More From The Market Online

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.
WELL Health - Hamed Shahbazi, Founder and CEO (third from right).

WELL Health streamlining business towards profitable growth

WELL Health (TSX:WELL) has made an integration update to streamline its business operations and position itself for profitable growth.

An investor’s gateway into the cancer immunotherapy market is with this Canadian biotechnology company 

The overarching cancer immunotherapy market continues growing at unprecedented rates, and BioVaxys Technology is ready to capitalize on it.

Buzz on the Bullboards: Where volatility meets opportunity

Some indices hit lows not seen in nearly a year after a concerning inflation report, only to bounce back the next day.